Abstract 5786: Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution through multi-omics analysis

Abstract Targeted Protein Degradation (TPD) is considered one of the new drug discovery strategies that could address previously “undruggable” disease targets through the ubiquitin-proteasome system (UPS). Although the current Target Protein Centric approach has proven successful in many cases, especially with well-validated E3 ligases such as CRBN and VHL, there is still a strong need to identify potential target protein degraders (PROTACs, molecular glues, etc.) through both target-centric and target-agnostic approaches. This would not only explore and identify potential tissue-specific novel E3 ligases but also greatly expand the range of potential degradable disease targets. In this study, we first developed a molecular glue-focused library consisting of approximately 5,000 compounds through various medicinal chemistry evaluations. A GSPT1-HiBit cell line and a GSPT1-CRBN-KO counter cell line were developed for primary hit screening purposes. More than 100 potential hits were identified through the initial screening, which included both CRBN-dependent and CRBN-independent hits. A GSPT1-based proximity labeling cell line was then constructed for further target deconvolution purposes via proteomics. Potential candidate E3 ligases were subsequently validated using an array-based expression manipulation strategy. Additionally, we tested novel synthetic lethal target discovery through both in vitro and in vivo screens, followed by omics-based target validation. Using a CRBN-focused glue library, we combined both transcriptomics and proteomics assays to evaluate potential “degradable” targets. To sum up, our study demonstrates that integrated target discovery and target deconvolution strategies could be useful for TPD drug discovery as well as other disease scenarios. Citation Format: Tongrui Hao, Yi Chen, Yan Gao, Jing Wen, Wenzhang Chen, Zhongyao Ma, Letian Kuai, Wenji Su, . Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution through multi-omics analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5786.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-5786
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 5786: Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution through multi-omics analysis

Letian Kuai, Yan Gao, Tongrui Hao, Yi Chen et al.
Cancer Research
Protein Degradation and Inhibitors
article

Abstract 5786: Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution through multi-omics analysis

Letian Kuai, Yan Gao, Tongrui Hao, Yi Chen, Zhongyao Ma, Wenzhang Chen, Wenji Su, Jing Wen
article en

Abstract

Abstract Targeted Protein Degradation (TPD) is considered one of the new drug discovery strategies that could address previously “undruggable” disease targets through the ubiquitin-proteasome system (UPS). Although the current Target Protein Centric approach has proven successful in many cases, especially with well-validated E3 ligases such as CRBN and VHL, there is still a strong need to identify potential target protein degraders (PROTACs, molecular glues, etc.) through both target-centric and target-agnostic approaches. This would not only explore and identify potential tissue-specific novel E3 ligases but also greatly expand the range of potential degradable disease targets. In this study, we first developed a molecular glue-focused library consisting of approximately 5,000 compounds through various medicinal chemistry evaluations. A GSPT1-HiBit cell line and a GSPT1-CRBN-KO counter cell line were developed for primary hit screening purposes. More than 100 potential hits were identified through the initial screening, which included both CRBN-dependent and CRBN-independent hits. A GSPT1-based proximity labeling cell line was then constructed for further target deconvolution purposes via proteomics. Potential candidate E3 ligases were subsequently validated using an array-based expression manipulation strategy. Additionally, we tested novel synthetic lethal target discovery through both in vitro and in vivo screens, followed by omics-based target validation. Using a CRBN-focused glue library, we combined both transcriptomics and proteomics assays to evaluate potential “degradable” targets. To sum up, our study demonstrates that integrated target discovery and target deconvolution strategies could be useful for TPD drug discovery as well as other disease scenarios. Citation Format: Tongrui Hao, Yi Chen, Yan Gao, Jing Wen, Wenzhang Chen, Zhongyao Ma, Letian Kuai, Wenji Su, . Novel non-CRBN based molecular glue identification and corresponding E3 ligase target deconvolution through multi-omics analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5786.

Cancer ResearchVol. 86(7_Supplement)
WuXi AppTec (China) (CN)
Good health and well-being
Openalex Percentile: Top 28%
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.